{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:27:00Z","timestamp":1785770820705,"version":"3.56.0"},"reference-count":191,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA029127"],"award-info":[{"award-number":["DA029127"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES012241"],"award-info":[{"award-number":["ES012241"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000182","name":"US Army Medical Research Acquisition Activity (USAMRAA)","doi-asserted-by":"publisher","award":["W81XWH-12-1-0536"],"award-info":[{"award-number":["W81XWH-12-1-0536"]}],"id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bcp.2015.07.027","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T21:58:12Z","timestamp":1438207092000},"page":"388-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders"],"prefix":"10.1016","volume":"97","author":[{"given":"Alvin V.","family":"Terry Jr.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina M.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.07.027_bib0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.bcp.2015.07.027_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/483269a","article-title":"Drug research: a plan for mental illness","volume":"483","author":"Insel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2015.07.027_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drudis.2012.08.003","article-title":"Something\u2019s got to give: psychiatric disease on the rise and novel drug development on the decline","volume":"18","author":"Chandler","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2015.07.027_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddstr.2011.09.007","article-title":"Drug repurposing through nonhypothesis driven phenotypic screening","volume":"8","author":"Reaume","year":"2011","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.bcp.2015.07.027_bib0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10822-011-9447-8","article-title":"The reductionist paradox: are the laws of chemistry and physics sufficient for the discovery of new drugs","volume":"25","author":"Maggiora","year":"2011","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bcp.2015.07.027_bib0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.bcp.2015.07.027_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","article-title":"Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders","volume":"26","author":"Youdim","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2015.07.027_bib0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.drudis.2010.06.006","article-title":"Drug profiling: knowing where it hits","volume":"15","author":"Merino","year":"2010","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.bcp.2015.07.027_bib0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0301-0082(97)00050-6","article-title":"Diffuse transmission by acetylcholine in the CNS","volume":"53","author":"Descarries","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2015.07.027_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0169-328X(00)00031-0","article-title":"Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients","volume":"76","author":"Burghaus","year":"2000","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1471-4159.2000.0740237.x","article-title":"Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer\u2019s disease","volume":"74","author":"Guan","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2015.07.027_bib0075","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bcp.2007.05.023","article-title":"Heterogeneity and complexity of native brain nicotinic receptors","volume":"74","author":"Gotti","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0080","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1126\/science.7569895","article-title":"Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors","volume":"269","author":"McGehee","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bcp.2015.07.027_bib0085","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1523\/JNEUROSCI.19-10-03701.1999","article-title":"Nicotinic acetylcholine receptors containing alpha7 subunits are required for reliable synaptic transmission in situ","volume":"19","author":"Chang","year":"1999","journal-title":"J. Neurosci."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2015.07.027_bib0090","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1469-7793.1999.769ab.x","article-title":"Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices","volume":"515","author":"Hefft","year":"1999","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0014-5793(97)00600-5","article-title":"Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons","volume":"411","author":"Messi","year":"1997","journal-title":"FEBS lett."},{"key":"10.1016\/j.bcp.2015.07.027_bib0100","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1523\/JNEUROSCI.18-17-06871.1998","article-title":"Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells","volume":"18","author":"Berger","year":"1998","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0105","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1523\/JNEUROSCI.2444-07.2007","article-title":"Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1\/2 and CREB phosphorylation pathways","volume":"27","author":"Bitner","year":"2007","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.110.167213","article-title":"In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer\u2019s disease","volume":"334","author":"Bitner","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0166-4328(00)00211-4","article-title":"The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer\u2019s disease: studies with DMXBA (GTS-21)","volume":"113","author":"Kem","year":"2000","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0120","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","article-title":"Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization","volume":"184","author":"Levin","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002130050667","article-title":"Nicotinic acetylcholine involvement in cognitive function in animals","volume":"138","author":"Levin","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002130050671","article-title":"Nicotine enhances sustained attention in the rat under specific task conditions","volume":"138","author":"Mirza","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0924-977X(99)00002-4","article-title":"Nicotine improves memory in an object recognition task in rats","volume":"9","author":"Puma","year":"1999","journal-title":"Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0024-3205(88)90318-9","article-title":"Nicotine enhances delayed matching-to-sample performance by primates","volume":"43","author":"Elrod","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0197-4580(91)90102-P","article-title":"Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys","volume":"12","author":"Buccafusco","year":"1991","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bcp.2015.07.027_bib0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cercor\/8.2.164","article-title":"Age-related differences in distractibility and response to methylphenidate in monkeys","volume":"8","author":"Prendergast","year":"1998","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.bcp.2015.07.027_bib0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s002130050931","article-title":"Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer\u2019s disease","volume":"143","author":"White","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0031-6865(99)00047-3","article-title":"Nicotinic systems in central nervous systems disease: degenerative disorders and beyond","volume":"74","author":"Newhouse","year":"2000","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.bcp.2015.07.027_bib0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130100899","article-title":"Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers","volume":"159","author":"Min","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0170","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.154.6.797","article-title":"The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type","volume":"154","author":"Sahakian","year":"1989","journal-title":"Br. J. Psychiatry J. Mental Sci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0175","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.neubiorev.2005.02.006","article-title":"Nicotine use in schizophrenia: the self medication hypotheses","volume":"29","author":"Kumari","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2015.07.027_bib0180","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2741\/2695","article-title":"Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease","volume":"13","author":"Picciotto","year":"2008","journal-title":"Front. Biosci. J. Virtual Lib."},{"key":"10.1016\/j.bcp.2015.07.027_bib0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1212\/WNL.0b013e31823efcbb","article-title":"Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial","volume":"78","author":"Newhouse","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0190","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0091-3057(97)80001-9","article-title":"Safety of cotinine in humans: physiologic, subjective, and cognitive effects","volume":"57","author":"Hatsukami","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2015.07.027_bib0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1146\/annurev.pa.36.040196.003121","article-title":"Pharmacology of nicotine: addiction and therapeutics","volume":"36","author":"Benowitz","year":"1996","journal-title":"Annual Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0200","first-page":"8","article-title":"Nicotine as a discriminative stimulus to behavior: its characterization and relevance to smoking behavior","volume":"5","author":"Rosecrans","year":"1979","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.bcp.2015.07.027_bib0205","first-page":"6","article-title":"Cotinine inhibits amyloid-\u03b2 peptide neurotoxicity and oligomerization","volume":"S1","author":"Burgess","year":"2011","journal-title":"J. Clinic. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0210","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.bmcl.2014.02.008","article-title":"Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer\u2019s disease","volume":"24","author":"Gao","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2015.07.027_bib0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1527-3458.2005.tb00045.x","article-title":"Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition","volume":"11","author":"Terry","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.bcp.2015.07.027_bib0220","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3233\/JAD-2011-102136","article-title":"Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice","volume":"24","author":"Echeverria","year":"2011","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"10.1016\/j.bcp.2015.07.027_bib0225","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fnagi.2014.00162","article-title":"Cotinine halts the advance of Alzheimer\u2019s disease-like pathology and associated depressive-like behavior in Tg6799 mice","volume":"6","author":"Patel","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0230","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bcp.2011.12.043","article-title":"The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats","volume":"83","author":"Terry","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0235","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bcp.2009.06.102","article-title":"A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists","volume":"78","author":"Buccafusco","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0240","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1037\/bne0000021","article-title":"Cotinine reduces depressive-like behavior and hippocampal vascular endothelial growth factor downregulation after forced swim stress in mice","volume":"128","author":"Grizzell","year":"2014","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0245","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-3565(25)22334-5","article-title":"(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization","volume":"270","author":"Arneric","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0250","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1021\/jm960328w","article-title":"(S)-(\u2212)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors","volume":"39","author":"Cosford","year":"1996","journal-title":"J.Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.027_bib0255","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/jm000249r","article-title":"(\u2013)-Spiro[1-azabicyclo[2. 2. 2]octane-3,5\u2032-oxazolidin-2\u2032-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor","volume":"43","author":"Mullen","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.027_bib0260","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0006-8993(94)01449-R","article-title":"Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21","volume":"674","author":"Arendash","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0091-3057(96)00354-1","article-title":"Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo","volume":"57","author":"Briggs","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2015.07.027_bib0270","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0022-3565(25)22339-4","article-title":"S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization","volume":"270","author":"Decker","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0275","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002130000531","article-title":"Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression","volume":"152","author":"Ferguson","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0280","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00008877-199911000-00014","article-title":"AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats","volume":"10","author":"Levin","year":"1999","journal-title":"Behavioural Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0285","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s002130050538","article-title":"Central nicotinic receptor agonists ABT-418, ABT-089, and (\u2212)-nicotine reduce distractibility in adult monkeys","volume":"136","author":"Prendergast","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0290","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3565(24)34957-2","article-title":"Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys","volume":"290","author":"Schneider","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0295","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s002130050573","article-title":"Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice","volume":"136","author":"Stevens","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0300","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0305","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s002130050897","article-title":"Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer\u2019s disease","volume":"142","author":"Potter","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0310","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1176\/ajp.156.12.1931","article-title":"A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder","volume":"156","author":"Wilens","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0315","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0022-3565(24)37015-6","article-title":"ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys","volume":"283","author":"Decker","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0320","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bcp.2009.05.030","article-title":"TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia","volume":"78","author":"Hauser","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0325","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0278-5846(02)00205-1","article-title":"Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents","volume":"26","author":"Obinu","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0330","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","article-title":"EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors","volume":"62","author":"Prickaerts","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0335","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/jpet.110.171892","article-title":"RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents","volume":"336","author":"Wallace","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0340","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.112.197970","article-title":"Effects of the novel alpha7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA\/2 mice: pharmacodynamic characterization","volume":"343","author":"Radek","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0345","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bcp.2009.05.033","article-title":"Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition","volume":"78","author":"Rollema","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0350","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuroscience.2015.04.017","article-title":"Selective activation of alpha7 nicotinic acetylcholine receptor by PHA-543613 improves Abeta25-35-mediated cognitive deficits in mice","volume":"298","author":"Sadigh-Eteghad","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2015.07.027_bib0355","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0269881110367727","article-title":"A randomized double-blind study comparing 25 and 50mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment","volume":"25","author":"Dunbar","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0360","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-2011-101554","article-title":"Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer\u2019s disease: a phase IIb dose-finding study","volume":"24","author":"Frolich","year":"2011","journal-title":"Alzheimer\u2019s Dis. JAD"},{"key":"10.1016\/j.bcp.2015.07.027_bib0365","doi-asserted-by":"crossref","DOI":"10.1097\/WAD.0000000000000093","article-title":"Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease","author":"Lenz","year":"2015","journal-title":"Alzheimer Dis. A. Disorders"},{"key":"10.1016\/j.bcp.2015.07.027_bib0370","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bcp.2011.06.034","article-title":"Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease","volume":"82","author":"Wallace","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0375","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.2015.995639","article-title":"Safety and clinical effects of EVP-6124 in subjects with Alzheimer\u2019s disease currently or previously receiving an acetylcholinesterase inhibitor medication","volume":"15","author":"Deardorff","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bcp.2015.07.027_bib0380","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bcp.2013.04.001","article-title":"Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex","volume":"85","author":"Wallace","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0385","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1523\/JNEUROSCI.5712-09.2010","article-title":"Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling","volume":"30","author":"Parikh","year":"2010","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0390","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00213-013-3373-5","article-title":"The alpha-7 nicotinic receptor partial agonist\/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release","volume":"231","author":"Huang","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0395","first-page":"161","article-title":"Attention","volume":"228","author":"Callahan","year":"2015"},{"key":"10.1016\/j.bcp.2015.07.027_bib0400","first-page":"1391","volume":"35","author":"Howe","year":"2010"},{"key":"10.1016\/j.bcp.2015.07.027_bib0405","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002130050991","article-title":"Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats","volume":"144","author":"McGaughy","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0410","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pbb.2009.12.019","article-title":"ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects","volume":"95","author":"Mohler","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2015.07.027_bib0415","first-page":"891","volume":"29","author":"Young","year":"2004"},{"key":"10.1016\/j.bcp.2015.07.027_bib0420","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00213-006-0549-2","article-title":"Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task","volume":"189","author":"Hoyle","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0425","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.euroneuro.2006.03.008","article-title":"Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice","volume":"17","author":"Young","year":"2007","journal-title":"Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0430","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pnpbp.2008.11.018","article-title":"Effect of R3487\/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats","volume":"33","author":"Rezvani","year":"2009","journal-title":"Prog.Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0435","article-title":"R3487\/MEM3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques","author":"Wallace-Boone","year":"2009","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0440","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-859X-9-27","article-title":"A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia","volume":"9","author":"Shiina","year":"2010","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0445","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0166-4328(00)00305-3","article-title":"Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task","volume":"117","author":"Grottick","year":"2000","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0450","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbr.2012.11.028","article-title":"Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test","volume":"240","author":"Young","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0455","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00213-011-2393-2","article-title":"Efficacy and safety of the novel alpha(4) beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study","volume":"219","author":"Apostol","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0460","first-page":"405","volume":"38","author":"Bain","year":"2013"},{"key":"10.1016\/j.bcp.2015.07.027_bib0465","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biopsych.2013.06.002","article-title":"AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit\/hyperactivity disorder in adults","volume":"75","author":"Potter","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0470","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00213-013-3116-7","article-title":"A randomized, double-blind, placebo-controlled crossover study of alpha4beta 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit\/hyperactivity disorder","volume":"231","author":"Jucaite","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0475","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0006-3223(00)01027-1","article-title":"Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications","volume":"49","author":"Green","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0480","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.schbul.a033320","article-title":"Schizophrenia, sensory gating, and nicotinic receptors","volume":"24","author":"Adler","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2015.07.027_bib0485","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ajmg.1548","article-title":"Genetic linkage to schizophrenia at chromosome 15q14","volume":"105","author":"Freedman","year":"2001","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bcp.2015.07.027_bib0490","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0924-977X(00)00097-3","article-title":"Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia","volume":"10","author":"Gothelf","year":"2000","journal-title":"Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2015.07.027_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-3223(96)00302-2","article-title":"Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers","volume":"42","author":"Olincy","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0500","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0091-3057(96)00466-2","article-title":"Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models","volume":"57","author":"Stevens","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2015.07.027_bib0505","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1176\/ajp.150.12.1856","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients","volume":"150","author":"Adler","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0510","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-005-0142-0","article-title":"Tropisetron improves deficient inhibitory auditory processing in DBA\/2 mice: role of alpha 7 nicotinic acetylcholine receptors","volume":"183","author":"Hashimoto","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0515","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.schres.2004.12.016","article-title":"Tropisetron improves deficits in auditory P50 suppression in schizophrenia","volume":"76","author":"Koike","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0520","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1176\/appi.ajp.2012.11081289","article-title":"Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia","volume":"169","author":"Zhang","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0525","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0530","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hup.286","article-title":"Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia","volume":"16","author":"Kumari","year":"2001","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0535","first-page":"2167","volume":"33","author":"Hong","year":"2008"},{"key":"10.1016\/j.bcp.2015.07.027_bib0540","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.schres.2006.05.022","article-title":"A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms","volume":"87","author":"George","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0545","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s00213-014-3509-2","article-title":"Effects of the nicotinic alpha7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats","volume":"231","author":"Callahan","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0550","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1021\/jm901692q","volume":"53","author":"Ghiron","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.027_bib0555","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainres.2010.07.037","article-title":"Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats","volume":"1353","author":"Kohnomi","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0560","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.108.150094","article-title":"Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders","volume":"329","author":"Roncarati","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0565","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archpsyc.63.12.1325","article-title":"Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function","volume":"63","author":"Swerdlow","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0570","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2009.07.006","article-title":"Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status","volume":"114","author":"Rabin","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0575","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","article-title":"Memory impairment in schizophrenia: a meta-analysis","volume":"156","author":"Aleman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0580","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2008.04.011","article-title":"The cognitive neuroscience of memory function and dysfunction in schizophrenia","volume":"64","author":"Ranganath","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0585","first-page":"17","volume":"32","author":"Pichat","year":"2007"},{"key":"10.1016\/j.bcp.2015.07.027_bib0590","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2004.05.016","article-title":"Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats","volume":"156","author":"de Lima","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0595","first-page":"455","volume":"25","author":"Lahti","year":"2001"},{"key":"10.1016\/j.bcp.2015.07.027_bib0600","first-page":"141","volume":"17","author":"Malhotra","year":"1997"},{"key":"10.1016\/j.bcp.2015.07.027_bib0605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR 180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0610","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2012.05.003","article-title":"The nicotinic alpha7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys","volume":"64","author":"Cannon","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0615","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2015.07.027_bib0620","first-page":"968","volume":"38","author":"Lieberman","year":"2013"},{"key":"10.1016\/j.bcp.2015.07.027_bib0625","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.pra.0000442935.15833.c5","article-title":"Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatr Pract."},{"key":"10.1016\/j.bcp.2015.07.027_bib0630","first-page":"1568","volume":"39","author":"Umbricht","year":"2014"},{"key":"10.1016\/j.bcp.2015.07.027_bib0635","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00213-013-3064-2","article-title":"A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia","volume":"228","author":"Noroozian","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0640","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bcp.2007.07.011","article-title":"Allosteric modulation of nicotinic acetylcholine receptors","volume":"74","author":"Bertrand","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0645","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bcpt.12361","article-title":"Targeting alpha4beta2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach","volume":"116","author":"Grupe","year":"2015","journal-title":"Basic Clinic. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0650","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1476-5381.2012.01989.x","article-title":"Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors","volume":"167","author":"Timmermann","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0655","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bcp.2011.06.044","article-title":"\u03b14\u03b22 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of \u03b14\u03b22 nAChR agonists in pain","volume":"82","author":"Lee","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0660","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bcp.2011.05.007","article-title":"Potentiation of analgesic efficacy but not side effects: co-administration of an alpha4beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats","volume":"82","author":"Zhu","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0665","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainres.2012.03.064","article-title":"Positive allosteric modulation of alpha4beta2 nAChR agonist induced behaviour","volume":"1458","author":"Rode","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0670","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2013.12.008","article-title":"Neuropharmacological modulation of the P3-like event-related potential in a rat two-tone auditory discrimination task with modafinil and NS9283, a positive allosteric modulator of alpha4beta2 nAChRs","volume":"79","author":"Grupe","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0675","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00213-013-3207-5","article-title":"Discriminative-stimulus effects of NS9283, a nicotinic \u03b14\u03b22* positive allosteric modulator, in nicotine-discriminating rats","volume":"231","author":"Mohler","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0680","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.107.120436","article-title":"An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo","volume":"323","author":"Timmermann","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0685","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.0701321104","article-title":"Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators","volume":"104","author":"Ng","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.bcp.2015.07.027_bib0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2015.04.018","article-title":"Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats","author":"Nikiforuk","year":"2015","journal-title":"Eur. Neuropsychopharmacol. Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0695","doi-asserted-by":"crossref","first-page":"8352","DOI":"10.1021\/jm400704g","article-title":"Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of alpha7 nicotinic acetylcholine receptors","volume":"56","author":"Hogenkamp","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.027_bib0700","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1124\/jpet.108.146514","article-title":"Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B\/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide)","volume":"328","author":"Dunlop","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0705","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2012.10.019","article-title":"Positive allosteric modulator of alpha7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates","volume":"67","author":"Callahan","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0710","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00213-011-2535-6","article-title":"Effects of alpha7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis","volume":"220","author":"Kohlhaas","year":"2012","journal-title":"Psychopharmacology."},{"key":"10.1016\/j.bcp.2015.07.027_bib0715","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1177\/0269881111431747","article-title":"PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats","volume":"26","author":"McLean","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0720","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1124\/jpet.113.210963","article-title":"Characterization of RO5126946, a Novel \u03b17 nicotinic acetylcholine receptor-positive allosteric modulator","volume":"350","author":"Sahdeo","year":"2014","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0725","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1523\/JNEUROSCI.5269-04.2005","article-title":"A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization","volume":"25","author":"Hurst","year":"2005","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0730","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainres.2015.02.044","article-title":"Maximizing the effect of an alpha7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits","volume":"1611","author":"Stevens","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0735","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1124\/jpet.110.173245","article-title":"Characterization of 2-[[4-fluoro-3-(trifluoromethyl) phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor","volume":"336","author":"Dinklo","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0740","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuropharm.2012.06.040","article-title":"Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study","volume":"64","author":"Winterer","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0745","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1523\/JNEUROSCI.15-02-01455.1995","article-title":"Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired","volume":"15","author":"Quirion","year":"1995","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0750","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1371\/journal.pbio.0020404","volume":"2","author":"Powledge Nicotine as therapy","year":"2004","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0755","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neuropharm.2012.08.004","article-title":"Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history","volume":"64","author":"Gould","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0760","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder","volume":"110","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0765","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000355373","article-title":"crossover trial of varenicline in mild-to-moderate Alzheimer\u2019s disease","volume":"37","author":"Kim","year":"2014","journal-title":"Dement. Geriatr. Cogni. Disorders"},{"key":"10.1016\/j.bcp.2015.07.027_bib0770","first-page":"660","volume":"37","author":"Shim","year":"2012"},{"key":"10.1016\/j.bcp.2015.07.027_bib0775","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0006-8993(96)00063-7","article-title":"In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418","volume":"719","author":"Donnelly-Roberts","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0780","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bcp.2007.07.010","article-title":"Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys","volume":"74","author":"Buccafusco","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0785","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-3565(24)37422-1","article-title":"ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization","volume":"285","author":"Donnelly-Roberts","year":"1998","journal-title":"J. Pharmacol Exp Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0790","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.pain.2012.01.009","article-title":"Efficacy and safety of the \u03b14\u03b22 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain","volume":"153","author":"Rowbotham","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2015.07.027_bib0795","doi-asserted-by":"crossref","first-page":"9181","DOI":"10.1021\/jm3006542","article-title":"Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3. 3. 0]octane (TC-6683, AZD1446), a novel highly selective \u03b14\u03b22 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders","volume":"55","author":"Mazurov","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.027_bib0800","article-title":"AZD1446 (TC -6683), a novel alpha4beta2 nAChR agonist with cognitive-enhancing properties","author":"Szeliga","year":"2012","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0805","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0810","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-003-1668-7","article-title":"AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors","volume":"172","author":"Van Kampen","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0815","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0091-3057(96)00516-3","article-title":"Different effects of tropisetron and ondansetron in learning and memory paradigms","volume":"56","author":"Pitsikas","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2015.07.027_bib0820","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2013.12.029","article-title":"The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer\u2019s model","volume":"1551","author":"Spilman","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2015.07.027_bib0825","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/FBP.0b013e32835a7c31","article-title":"Tropisetron, a 5-HT(3) receptor antagonist, enhances object exploration in intact female rats","volume":"23","author":"Sawyer","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0830","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/jpet.105.093047","article-title":"Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats","volume":"316","author":"Hernandez","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0835","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.neuropharm.2006.08.025","article-title":"Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats","volume":"52","author":"Hohnadel","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2015.07.027_bib0840","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","article-title":"Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations","volume":"82","author":"Williams","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0845","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)37014-4","article-title":"ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties","volume":"283","author":"Sullivan","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0850","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1527-3458.2004.tb00011.x","article-title":"ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders","volume":"10","author":"Rueter","year":"2004","journal-title":"CNS Drug Rev."},{"issue":"February (2)","key":"10.1016\/j.bcp.2015.07.027_bib0855","doi-asserted-by":"crossref","first-page":"e0117223","DOI":"10.1371\/journal.pone.0117223","article-title":"Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties","volume":"10","author":"Menze","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.07.027_bib0860","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/S0024-3205(03)00226-1","article-title":"The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Invited Minireview","volume":"72","author":"Buccafusco","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0865","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bcp.2009.06.102","article-title":"A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists","volume":"78","author":"Buccafusco","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.027_bib0870","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.114.219881","article-title":"R-(+)\u2014and S-(\u2212)\u2014Isomers of Cotinine Augment Cholinergic Responses in vitro and in vivo","volume":"352","author":"Terry","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2015.07.027_bib0875","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00213-012-2895-6","article-title":"Effects of chronic sazetidine-A, a selective \u03b14\u03b22 neuronal nicotinic acetylcholine receptors desensitizing agent on pharmacologically-induced impaired attention in rats","volume":"226","author":"Rezvani","year":"2013","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2015.07.027_bib0880","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/ALN.0b013e3181834490","article-title":"Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug","volume":"109","author":"Cucchiaro","year":"2008","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.bcp.2015.07.027_bib0885","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.166280","article-title":"Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior","volume":"334","author":"Turner","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2015.07.027_bib0890","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/JMN:30:1:19","article-title":"a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties","volume":"30","author":"Lippiello","year":"2006","journal-title":"J. Mol. Neurosci."},{"issue":"Summer (2)","key":"10.1016\/j.bcp.2015.07.027_bib0895","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1527-3458.2004.tb00010.x","article-title":"TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects","volume":"10","author":"Gatto","year":"2004","journal-title":"CNS Drug Rev."},{"issue":"6","key":"10.1016\/j.bcp.2015.07.027_bib0900","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.neubiorev.2005.02.006","article-title":"Nicotine use in schizophrenia: the self medication hypotheses","volume":"29","author":"Kumari","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2015.07.027_bib0905","doi-asserted-by":"crossref","first-page":"10093","DOI":"10.1523\/JNEUROSCI.23-31-10093.2003","article-title":"Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and l-type calcium channel inactivation","volume":"31","author":"Stevens","year":"2003","journal-title":"J. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2015.07.027_bib0910","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JAD-2011-110173","article-title":"Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"24","author":"Kawamata","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"1","key":"10.1016\/j.bcp.2015.07.027_bib0915","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.brainres.2006.05.023","article-title":"Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor","volume":"1101","author":"Serres","year":"2006","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.bcp.2015.07.027_bib0920","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.neuroscience.2009.12.073","article-title":"Nicotine increases the expression of neurotrophin receptor tyrosine kinase receptor A in basal forebrain cholinergic neurons","volume":"166","author":"Formaggio","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2015.07.027_bib0925","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1054-3589(08)60950-3","article-title":"The pharmacology of (\u2212)-nicotine and novel cholinergic channel modulators","volume":"37","author":"Brioni","year":"1997","journal-title":"Ad.v Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2015.07.027_bib0930","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0022-3565(24)38240-0","article-title":"Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit","volume":"289","author":"Marks","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.027_bib0935","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.ne.16.030193.002155","article-title":"The diversity of neuronal nicotinic acetylcholine receptors","volume":"16","author":"Sargent","year":"1993","journal-title":"Annual Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2015.07.027_bib0940","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0166-2236(96)10073-4","article-title":"Presynaptic nicotinic ACh receptors","volume":"20","author":"Wonnacott","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2015.07.027_bib0945","series-title":"Nicotinic Receptors in the Nervous System","author":"Levin","year":"2001"},{"key":"10.1016\/j.bcp.2015.07.027_bib0950","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.bcp.2015.07.027_bib0955","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrd2927","article-title":"Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system","volume":"8","author":"Taly","year":"2009","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215004165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215004165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:14:30Z","timestamp":1748549670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215004165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":191,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0006295215004165"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.027","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}